The safe, tolerability, and efficacy of once-daily memantine (28mg): a multinational, randomized, placebo-controlled trial in patients with moderate to severe Alzheimer's disease taking cholinesterase inhibitor | ||
| dc.conicet.organizacion | Saint Louis University School of Medicine | |
| dc.conicet.organizacion | Instituto de Neurología Cognitiva | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea" | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Institutos Nacionales de Salud de México. Instituto de Geriatría | |
| dc.conicet.organizacion | PsicoMedica Clinical and Research Group | |
| dc.conicet.organizacion | Forest Research Institute | |
| dc.conicet.organizacion | Forest Research Institute | |
| dc.conicet.organizacion | Prescott Medical Communications Group | |
| dc.conicet.organizacion | Prescott Medical Communications Group | |
| dc.conicet.organizacion | Forest Research Institute | |
| dc.conicet.organizacion | Forest Research Institute | |
| dc.contributor.author | Grossberg, George T. | |
| dc.contributor.author | Manes, Facundo Francisco | |
| dc.contributor.author | Allegri, Ricardo Francisco | |
| dc.contributor.author | Gutiérrez Robledo, Luis Miguel | |
| dc.contributor.author | Gloger, Sergio | |
| dc.contributor.author | Xie, Lei | |
| dc.contributor.author | Jia, X. Daniel | |
| dc.contributor.author | Pejoviç, Vojislav | |
| dc.contributor.author | Miller, Michel L. | |
| dc.contributor.author | Perhach, James | |
| dc.contributor.author | Graham, Stephen M. | |
| dc.date.issued | 2013-06 | |
| dc.description.abstract | INTRODUCTION: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer's disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors. METHODS: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of 3-14) were randomized to receive once-daily, 28-mg, extended-release memantine or placebo. Co-primary efficacy parameters were the baseline-to-endpoint score change on the Severe Impairment Battery (SIB) and the endpoint score on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus). The secondary efficacy parameter was the baseline-to-endpoint score change on the 19-item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19); additional parameters included the baseline-to-endpoint score changes on the Neuropsychiatric Inventory (NPI) and verbal fluency test. Data were analyzed using a two-way analysis of covariance model, except for CIBIC-Plus (Cochran-Mantel-Haenszel test). Safety and tolerability were assessed through adverse events and physical and laboratory examinations. RESULTS: A total of 677 patients were randomized to receive extended-release memantine (n = 342) or placebo (n = 335); completion rates were 79.8 and 81.2 %, respectively. At endpoint (week 24, last observation carried forward), memantine-treated patients significantly outperformed placebo-treated patients on the SIB (least squares mean difference [95 % CI] 2.6 [1.0, 4.2]; p = 0.001), CIBIC-Plus (p = 0.008), NPI (p = 0.005), and verbal fluency test (p = 0.004); the effect did not achieve significance on ADCS-ADL19 (p = 0.177). Adverse events with a frequency of ≥5.0 % that were more prevalent in the memantine group were headache (5.6 vs. 5.1 %) and diarrhea (5.0 vs. 3.9 %). CONCLUSION: Extended-release memantine was efficacious, safe, and well tolerated in this population. | es |
| dc.description.fil | Fil: Grossberg, George T.. Saint Louis University School of Medicine; Estados Unidos | |
| dc.description.fil | Fil: Manes, Facundo Francisco. Instituto de Neurología Cognitiva; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.description.fil | Fil: Allegri, Ricardo Francisco. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.description.fil | Fil: Gutiérrez Robledo, Luis Miguel. Institutos Nacionales de Salud de México. Instituto de Geriatría; México | |
| dc.description.fil | Fil: Gloger, Sergio. PsicoMedica Clinical and Research Group; Chile | |
| dc.description.fil | Fil: Xie, Lei. Forest Research Institute; Estados Unidos | |
| dc.description.fil | Fil: Jia, X. Daniel. Forest Research Institute; Estados Unidos | |
| dc.description.fil | Fil: Pejoviç, Vojislav. Prescott Medical Communications Group; Estados Unidos | |
| dc.description.fil | Fil: Miller, Michel L.. Prescott Medical Communications Group; Estados Unidos | |
| dc.description.fil | Fil: Perhach, James. Forest Research Institute; Estados Unidos | |
| dc.description.fil | Fil: Graham, Stephen M.. Forest Research Institute; Estados Unidos | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Grossberg, George T.; Manes, Facundo Francisco; Allegri, Ricardo Francisco; Gutiérrez Robledo, Luis Miguel; Gloger, Sergio; et al.; The safe, tolerability, and efficacy of once-daily memantine (28mg): a multinational, randomized, placebo-controlled trial in patients with moderate to severe Alzheimer's disease taking cholinesterase inhibitor; Springer; Cns Drugs; 27; 6; 6-2013; 469-478 | es |
| dc.identifier.eissn | 1179-1934 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1172-7047 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/24718 | |
| dc.journal.ciudad | Berlín | es |
| dc.journal.number | 6 | es |
| dc.journal.pagination | 469-478 | es |
| dc.journal.pais | Alemania | es |
| dc.journal.title | Cns Drugs | es |
| dc.journal.volume | 27 | es |
| dc.language.iso | eng | es |
| dc.publisher | Springer | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs40263-013-0077-7 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40263-013-0077-7 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680656/ | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | Alzheimer | es |
| dc.subject | Memantine | es |
| dc.subject | Trial | es |
| dc.subject | Once-Daily | es |
| dc.subject.classification | Reumatología | es |
| dc.subject.classification | Medicina Clínica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | The safe, tolerability, and efficacy of once-daily memantine (28mg): a multinational, randomized, placebo-controlled trial in patients with moderate to severe Alzheimer's disease taking cholinesterase inhibitor | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.9b2d5fec-604f-40a2-bae3-7e6a99e6c0d7_A.pdf
- Tamaño:
- 332.48 KB
- Formato:
- Adobe Portable Document Format
- Descripción: